In pancreatic ductal adenocarcinoma, it was shown that immunotherapy using anti-PD-L1 can be potentiated with epigenetic therapy (DZNep and 5-AZA) by increasing cancer-associated antigen expression and increasing T cell trafficking across the immunosuppressive tumor microenvironment [30]. This evidence concerns the gene CD274 and pancreatic ductal adenocarcinoma.